Skip to content
etf.net

BBP vs GNMX

Virtus Biotech ETF

BBPANYSE Arca

Corgi Genomics & Precision Medicine ETF

GNMXCCboe

Overlap

Expense ratio

BBP −0.01pt a year

BBP0.34%GNMX0.35%

Avg volume · 30D

BBP 6.6×the volume

BBP11.7KGNMX1.79K

BBP vs GNMX Performance

Jul 31, 2026 – Oct 30, 2026

+11.0%BBP+28.1%GNMX

Jul 31, 2026 to Oct 30, 2026. BBP +11.0%. GNMX +28.1%. Use the arrow keys to read each point.0%20%Jul 2026Sep 2026Oct 2026
Expense ratio
BBP 0.34%, better
GNMX 0.35%
Fund size
BBP $132M
GNMX $1M
1Y total return
BBP +39.6%
GNMX No data
Yield (12M)
BBP 0.00%
GNMX No data
Holdings
BBP 66
GNMX 58
Avg volume (30D)
BBP 11.7K sh, better
GNMX 1.79K sh
NAV per share
BBP $105.25
GNMX $38.06
52W range

ETF.net Grade

BBP: Cost 94, Risk 64, Mission 83, Tradability 31, Holdings 82, Durability 55. GNMX: Cost 81, Risk 71, Mission not scored, Tradability 17, Holdings 49, Durability 0.
Pillar letters and Scores for BBP, GNMX, with each pillar’s weight
PillarBBPGNMX
Cost30% weightA94HigherA81
Mission25% weightA83Not scored
Risk15% weightB64A71Higher
Tradability15% weightD31HigherF17
Holdings10% weightA82HigherC49
Durability5% weightB55HigherF0

Rank among Biotech & Genomics funds

How we build Categories ›
Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

Same Category. BBP and GNMX are both graded against the same 17 Biotech & Genomics funds, so their Grades compare head to head.

Biotech & Genomics⁠

Category · 17 funds
See all 17 ›

BBP ranks 4th and GNMX 11th of 17 funds in the Biotech & Genomics Category.

  1. Rank 1AXBIState Street SPDR S&P Biotech ETFScore 80
  2. Rank 2AIBBQInvesco Nasdaq Biotechnology ETFScore 77
  3. Rank 3AIBBiShares Biotechnology ETFScore 75
  4. Rank 4ABBPVirtus Biotech ETFScore 74
  5. Rank 5BBBHVanEck Biotech ETFScore 68
  6. Rank 10CIBRNiShares Neuroscience and Healthcare ETFScore 43
  7. Rank 11CGNMXCorgi Genomics & Precision Medicine ETFScore 40
  8. Rank 11CWDNAWisdomTree BioRevolution FundScore 40

Our read on each fund

ETF.net Research

BBPAVirtus Biotech ETF

GNMXCCorgi Genomics & Precision Medicine ETF

In short

BBP Biotech, minus the coin flips. BBP tracks an index of US-listed biotech companies that already have at least one FDA-approved therapy, so the basket leans commercial-stage instead of clinical-trial hopefuls.

GNMX No data

Stated mandate

BBP The fund seeks to track the LifeSci Biotechnology Products Index, which consists of U.S.-listed biotechnology stocks with at least one FDA-approved drug therapy.

GNMX No data

Why people hold it

  • BBP The screen does the heavy lifting: index membership requires at least one FDA-approved drug therapy, which filters out pre-approval story stocks.
  • 0.34% a year undercuts the biotech cohort median of 0.50% and sits below IBB's 0.44%.
  • Running since 2014 and spread across roughly 200 US-listed names, so one approval or rejection does not decide the whole basket.
  • One of the stronger builds in its biotech and genomics peer group, with a portfolio that stays close to the index it promises.

GNMX No data

Worth knowing

  • BBP Thinly traded and modest in size next to the category's household names. Spreads can widen, which makes limit orders the safer habit.
  • Income is not the point here. The fund has not been paying distributions, so the return story is price.
  • An approved drug filters risk, it does not erase it. This is a single-sector biotech basket, and sector drawdowns hit everything in it.

GNMX No data

Full BBP profile⁠

Full GNMX profile⁠

BBP vs GNMX Holdings

How we measure overlap

Each holding counts at its smaller weight in the two funds, summed over the full Holdings. Sector, country and asset class use the same rule on each fund’s split. Cash, FX and derivative lines stay out of the counts. Two bond funds get no overlap figure.

BBP vs GNMX Cost

Overpaying GNMX vs BBP

$194

On $10,000 over 30 years. 7% growth a year before fees, expense ratio only.

  • BBP 0.34%

    $6,932

  • GNMX 0.35%

    $7,126

$10,000
30 years

Cost over time

  • BBP 0.34%
  • GNMX 0.35%
  • Overpaying
One line per fund, from year 0 to year 30. Use the arrow keys to read each point.$0$2K$4K$6K$8K051015202530GNMX $7,126BBP $6,932

Year by year

YearBBPGNMXOverpaying
10$616$634$18
20$2,386$2,454$68
30$6,932$7,126$194

Expense ratio

  • 0.34%BBP, cheaper
  • 0.35%GNMX
  • Middle half of Biotech & Genomics funds
  • Median 0.47%

BBP 2nd cheapest of 17 funds

GNMX 3rd cheapest of 17 funds

BBP vs GNMX Dividends

Last 12 months to Oct 30, 2026
Yield (12M)
BBP 0.00%
GNMX No data
Payout (12M)
BBP None
GNMX None

Distribution history

Per share, 2015 to 2017, same scale for both

BBP2 paymentsAll BBP payments⁠
One bar per payment. 2 payments from 2015 to 2017. Dec 21, 2015 $0.40; Dec 20, 2017 $0.07. Use the arrow keys to read each point.$0$0.252017
GNMXAll GNMX payments⁠

No distribution history available.

BBP vs GNMX Risk

Fall from peak · 5 years

This chart needs five years of history for both funds.

Risk facts

VolatilityStd dev, 3 years
BBP 18.7%GNMX No data
Return per unit of riskSharpe ratio, 3 years
BBP 1.30GNMX No data
Worst fallMax drawdown, 5 years
BBP −37.8%GNMX No data
Market sensitivityBeta, 5 years
BBP 0.77GNMX 2.27

Popular comparisons

  • BBPAvsXBIA

    Virtus Biotech ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.34% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • GNMXCvsXBIA

    Corgi Genomics & Precision Medicine ETF · State Street SPDR S&P Biotech ETF

    Expense ratio
    0.35% · 0.35%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBQA

    Virtus Biotech ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.34% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • GNMXCvsIBBQA

    Corgi Genomics & Precision Medicine ETF · Invesco Nasdaq Biotechnology ETF

    Expense ratio
    0.35% · 0.19%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • BBPAvsIBBA

    Virtus Biotech ETF · iShares Biotechnology ETF

    Expense ratio
    0.34% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.

  • GNMXCvsIBBA

    Corgi Genomics & Precision Medicine ETF · iShares Biotechnology ETF

    Expense ratio
    0.35% · 0.44%
    Category
    Same Category. Both funds are graded against the same funds, so their Grades compare head to head.